Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine Plus Oxaliplatin with Radiotherapy in Rectal Cancer
NCT02694718Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2005
- Primary completion
- Aug 2006
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in rectal cancer, sponsored by Roche. Primary endpoint: Pathological Complete Tumor Response. Started Mar 2005; status: completed.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02694718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02694718.